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S un'll'rl;try 
A number of antigens recognized by tumor-reactive T  cells have recently been identified. The 
antigens identified in mouse model systems appear, with one exception, to represent the prod- 
ucts of mutated genes. In contrast, most of the antigens recognized by human tumor-reactive T 
cells reported to date appear to represent the products of non-mutated genes. Here we report 
the isolation of a cDNA clone encoding [$-catenin, which was shown to be recognized by the 
tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line 
from patient 888. The cDNA clone, which was isolated from the autologous melanoma cDNA 
library,  differed by a  single  base pair from the  published  ~-catenin  sequence,  resulting in  a 
change from a serine to a phenylalanine residue at position 37. Normal tissues from this patient 
did not express the altered sequence, nor did 12 allogeneic melanomas, indicating that this rep- 
resented a  unique  mutation  in  this  patient's melanoma. A  peptide  corresponding to  the  se- 
quence between amino acids 29 and 37 of the mutant gene product was identified as the T  cell 
epitope recognized by TIL 1290. The olSservation that HLA-A24 binding peptides contain an 
aromatic or hydrophobic residue  at position 9  suggested that the  change at position 37  may 
have generated a peptide  (SYLDSGIHF) which was capable of binding to  HLA-A24, and a 
competitive binding assay confirmed this hypothesis. The [3-catenin protein has been shown 
previously to be involved in cell adhesion mediated through the cadherin family of cell surface 
adhesion molecules. The high frequency of mutations found in members of cellular adhesion 
complexes in a variety of cancers suggests that these molecules may play a role in development 
of the malignant phenotype. 
T 
he majority of murine antigens recognized by tumor- 
reactive T  cells represent the products of mutated genes 
(1,  2).  The only reported example of a non-mutated gene 
product recognized by tumor reactive T  cells in the mouse 
is the P1A antigen of the P815 mastocytoma, which is also 
expressed on some normal mast cell lines (3). A number of 
genes encoding antigens recognized by human melanoma- 
reactive T  cells have recently been isolated. The MAGE (4, 
5),  BAGE  (6),  and  GAGE  (7)  gene  products  are  non- 
mutated proteins  and  are  not  expressed in  normal  tissues 
with the exception  of testes, and thus  appear to represent 
tissue-specific antigens with a restricted pattern of expres- 
sion.  In  addition,  melanoma-reactive  T  cells  have  been 
shown to recognize tyrosinase (8, 9), MART-1  (10), gpl00 
(11), and TRP-1  (12).  Non-mutated epitopes were identi- 
fied in these proteins,  whose  expression in normal tissues 
was limited to  melanocytes and  retina.  Two reports have 
recently  appeared,  however,  demonstrating  that  human 
melanoma-reactive T  cells recognize mutant gene products 
(13,  14). 
The HLA-A24 restricted melanoma-reactive tumor-infil- 
trating lymphocyte (TIL) l  1290  cell line  established from 
patient 888 was recently shown to recognize the product of 
a newly described gene termed p15  (15).  This product ap- 
peared to be expressed in a wide variety of normal tissues, 
and  a  non-mutated peptide  from this  protein  was  recog- 
nized by TIL 1290.  This report presents the isolation of a 
second gene encoding an antigen recognized by TIL 1290. 
Two clones which were isolated by screening a cDNA li- 
brary  with  TIL  1290  represented  partial  cDNAs  derived 
from the [3-catenin gene. The T  cell epitope identified in 
1Abbreviations used in  this paper: mel, melanoma; TIL, tumor-infiltrating 
lymphocytes. 
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point mutation which gave rise  to  a  peptide with signifi- 
cantly enhanced binding to the HLA-A24 class I molecule. 
[3-catenin has been shown to be involved in the binding 
of members of the cadherin family of cell surface adhesion 
molecules to cytoplasmic actin microfilaments (reviewed in 
16),  and the  mutation described in this  report  may have 
functional significance for  the  development of the  malig- 
nant phenotype of this tumor. 
Materials and Methods 
Cell Lines.  The derivation of the 293-A24 stable transfectant 
of the 293 human kidney cell line expressing the HLA-A24 class I 
gene was previously described (9). The 293-A24 cells were main- 
tained in DMEM containing  7.5% FBS, and melanoma (reel) cell 
lines maintained in 1<PMI containing 5% FBS. Melanoma-spe- 
cific CTL were grown from TIL in AIM V (Life Technologies, 
Gaithersburg,  MD)  media  containing 5%  human  serum  plus 
6,000  IU/ml IL2 for 30-60 d, as previously described  (17). TIL 
888 was grown from a tumor derived in 1989 from patient 888, 
and when administered to  the  autologous patient with IL2  re- 
sulted  in  the  complete  regression  of multiple metastases.  TIL 
1290 was  grown  from  a  recurrent pelvic  mass in  patient  888 
found three  years later,  and  was  administered in  combination 
with TIL 888,  resulting in regression  of an additional pelvic  tu- 
mor mass. TIL 1541 was grown from a small subcutaneous nod- 
ule isolated from patient 888 in 1995. 
eDNA Library Construction and Screening.  The cDNA library was 
constructed using 10 I-~g  ofpoly (A) + m1<NA from the 1290 reel 
which had been doubly selected using the FastTrack polyA isola- 
tion kit (InVitrogen, San Diego, CA).  The eDNA was synthe- 
sized using a random primer eDNA synthesis kit (Promega,  Mad- 
ison, WI), BstXI adaptors (InVitrogen) were ligated to the eDNA, 
and the eDNA was then cloned into pCDNA3 (lnVitrogen) which 
had been digested  with  BstXI.  Follwing the  transformation of 
DH5a cells, the volume needed to obtain 50 bacterial  transfor- 
mants was calculated and used to innoculate 1 ml of Super Broth 
(Biofluids, Gaithersburg,  MD) in a 96-well culture block (AGCT, 
Gaithersburg,  MD) for 48 h. Plasmid DNA was then prepared us- 
ing the 9600 Wizard system (Promega Corp., Madison, WI). Tram- 
fection of 293-A24 was carried out using 200 ng ofplasmid DNA 
as previously  described  (15), 18-24 h later TIL were added,  and 
18-24 h later supernatants assayed for GM-CSF using a GM-CSF 
ELISA (R.&D Sys., Inc., Minneapolis, MN). 
Sequencing and PCR Analysis.  DNA sequencing was conducted 
using the  Sequenase  2.0  kit  (United States Biochemical Corp., 
Cleveland, OH). A search of the GenBank database was carried 
out using the Blast sequence alignment algorithm (18). To car  D  " 
out the reverse transcriptase (P-T) PC1< analysis, 5 p.g total cellu- 
lar 1<NA was reverse transcribed using oligo-dT, and 1/10 of this 
reaction then using to carry a PC1<. The PC1< was carried out for 
30 cycles at 95~  for 1 nfin, 60~  for 1 min and 72~  for 1 nfin. 
The  PC1< was  carried  out  using the  primers  60F  (5'-AAG- 
GTCTGAGGAGCAGCTTC-3')  and 7271< (5'-TGGACCAT- 
AACTGCAGCCTT-3'). 
Peptide Synthesis and Purification.  The peptides were synthesized 
on the Gilson AMS222  multiple peptide synthesizer  using stan- 
dard  F-moc chemistry.  Peptides  were purified on a R.2 reverse- 
phase HPLC column (PerSeptive  Biosystems, Framingham, MA) 
as well as a C8 column (VYDAC, Hesperia,  CA) using an aceto- 
nitrile gradient in water with 0.05% trifluoroacetic  acid, and were 
estimated to be >90% pure. 
Competitive Binding Assay.  A competitive peptide binding as- 
say using live cells was carried out as previously described (19) us- 
ing the HLA-A24 binding peptide AYIDNYNKF (20) and 888 
EBV B cells, which express high levels of the HLA-A24 class l 
gene product. Briefly, cells were incubated overnight at 26~  in 
the presence of [52-microglobulin,  and the following day cells in- 
cubated with l0  s cpm of the ~2SI-labeled  AYIDNYNKF peptide, 
[32-microglobulin,  and varying concentrations of unlabeled com- 
petitor peptides for 4 h at 20~  Following the incubation period, 
cell-bound and unbound peptides  were separated by centrifuga- 
tion through a mixture of pthalate  oils  (dioctyl/dibutyl: 1:1.1), 
and the pellets counted in a gamma counter. 
Results 
Isolation ofcDNA  Clones.  A eDNA library was prepared 
from 1290 melanoma and pools containing approximately 
50  cDNA  clones  were  screened  for  reactivity  with  TIL 
1290  by  transient transfection into the  recipient cell line 
293-A24.  This cell line was derived by stably transfecting 
the human kidney cell line 293 with the HLA-A24 class 1 
gene derived from the 888 melanoma cell line and sorting 
cells which expressed this gene product at high levels (9). 
Following the screening of 800 pools containing a total of 
"-'40,000 cDNAs two positive pools were isolated. Tram- 
fection of these pools into 293-A24 cells stimulated the re- 
lease  of  15  and  20  pg/ml  of GM-CSF  from  TIE  1290, 
whereas transfection of the other pools resulted in the stim- 
ulation of less than 10 pg/ml of GM-CSF. 
Individual clones were then isolated from the two posi- 
tive pools, and positive clones from each of the two pools, 
designated  11al  and  12g2,  were  identified which  stimu- 
lated  strong  cytokine  release  from  TIL  1290  following 
transfection into 293-A24 cells (Table 1). A comparable re- 
sponse was also seen using transfectants of p15, which had 
Table 1.  Antigen  Recognition by TIL  I290 and 888 
Stimulator 
cell line  Transfected gene  HLA-A24 
GM-CSF Release* 
TIL 1290  TIL 888 
pg/ml 
293-A24  p 15  +  820  10 
293-A24  12c2  +  610  15 
293-A24  11 a 1  +  470  12 
293-A24  Tyrosinase  +  30  1,700 
293-A24  None  +  30  11) 
888 mel  None  +  3,500  4,100 
624 reel  None  -  413  <8 
None  None  -  20  19 
*The release of cytokine from TIL 1291) and TIL 888 stmmlated by 
293-A24 transfectants  or melanomas  was measured following coincuba- 
tion with the TIEs for 24 h. 
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~-catenin  ~AGCAG  CGTTGGCCCG  GCCCCGGGAG  CGGAGAGCGA  GGGGAGGCGG  AGACGGAGGA 
12g2  .............................................. 
llal  GAACTGCTGA  GGGTTGTAGG  GGAT ...... 
120 
~-catenin  AGGTCTGAGG  AGCAGCTTCA  GTCCCCGCCG  AGCCGCCACC  GCAGGTCGAG  GACGGTCGGA 
12g2  ..............................................  .  ............. 
llal  ............................................................ 
180 
~-catenin  CTCCCGCGGC  GGGAGGAGCC  TGTTCCCCTG  AGGGTATTTG  AAGTATACCA  TACAACTGTT 
12g2  ...................................  -  ........................ 
llal  ............................................................ 
240 
M  A  T  Q  A  D  L  M  E  L  D  M  A 
~-catenin  TTGAAAATCC  AGCGTGGACA  ATGGCTACTC  AAC-CTGATTT  GATGGAGTTG  GACATGGCCA 
12g2  ............................................................ 
llal  ............................................................ 
300 
M  E  P  D  R  K  A  A  V  S  H  W  Q  Q  Q  S  Y  L  D  S 
~-catenin  TGGAACCAGA  CAGAAAAGCG  GCTGTTAGTC  ACTGGCAGCA  ACAGTCTTAC  CTGGACTCTG 
1292  ............................................................ 
llal  ............................................................ 
360 
G  I  H  S  G  A  T  T  T  A  P  S  L  S  G  K  G  N  P  E 
~-catenin  GAATCCATTC  TGGTGCCACT  ACCACAGCTC  CTTCTCTGAG  TGGTAAAGGC  AATCCTGAGG 
E 
1292  ......... T  .................................................. 
llal  ......... T  .................................................. 
420 
E  E  D  V  D  T  S  Q  V  L  Y  E  W  E  Q  G  F  S  Q  S 
~-catenin  AAGAGGATGT  GGATACCTCC  CAAGTCCTGT  ATGAGTGGGA  ACAGGGATTT  TCTCAGTCCT 
12g2  ............................................................ 
llal  ............................................................ 
48O 
F  T  Q  E  Q  V  A  D  I  D  G  Q  Y  A  M  T  R  A  Q  R 
~-catenin  TCACTCAAGA  ACAAGTAC-CT  GATATTGATG  GACAGTATGC  AATGACTCGA  GCTCAGAGGG 
12g2  ............................................................ 
llal  ............................................................ 
54O 
V  R  A  A  M  F  P  E  T  L  D  E  G  M  Q  I  P  S  T  Q 
~-catenin  TACGAGCTGC  TATGTTCCCT  GAGACATTAG  ATGAGGGCAT  GCAGATCCCA  TCTACACAGT 
1292  ............................................................ 
llal  ............................................................ 
600 
F  D  A  A  H  P  T  N  V  Q  R  L  A  E  P  S  Q  M  L  K 
~-catenin  TTGATGCTGC  TCATCCCACT  AATGTCCAGC  GTTTGGCTGA  ACCATCACAG  ATGCTGAAAC 
1292  ............................................................ 
llal  .......................................... 
660 
HAVVNLINYQDDAELATRAI 
~-catenin  A~CAGT~T  AAACT~A~  ~CTATC~G  A~ATGCAGA  ACTTGCCACA  CGTGC~TCC 
1292  ............................................................ 
720 
PELT  KLLNDEDQVVVNKAAV 
~-catenin  C~C~ACAAAACT~TA  ~ACGA~  ACCA~T~T  ~TT~T~G  ~TGCAGTTA 
1292  ............................................................ 
780 
MVHQLSKKEASRHAIMRSPQ 
~-catenin  TGGTCCATCA  GCTTTCTAAA  ~TT  CCAGACAC~  TATCAT~GT  TCTCCTCAGA 
1292  ............................................................ 
840 
MVSAIVRTMQNTNDVETARC 
~-catenin  T~TGTCT~  TAT~TACGTACCAT~AGAATACAAA~ATGTAGAAACA  ~TCGT~TA 
1292  ............................................................ 
89O 
TAGTLHNLSHHREGLLA 
~-catenin  CCGCTGGGAC  CTTGCAT~C  CTTTCCCATC  ATCGTGAGGG  CTTACTGGCC 
1292  .................................................. 
Figure I.  Sequence of the two 
[3-catenin cDNA clones. The se- 
quence of the two cDNA clones 
were aligned with the published 
[3-catenin  sequence,  GenBank 
accession number Zl9054  (29). 
The translated sequence is listed 
above  the  nucleotide  sequence, 
with  dashes  indicating  identity 
with the published sequence and 
periods indicating a gap in the 5' 
untranslated  region  of  clone 
12g2.  The sequence of the pep- 
tide  which represents the T  cell 
epitope is underlined. previously been shown to stimulate  TIL  1290, but no re- 
sponse was seen with transfectants expressing tyrosinase.  In 
contrast,  TIL 888  responded  to  transfectants  of tyrosinase 
but failed to respond to 293-A24 cells transfected with ei- 
ther the newly isolated clones or the p15 gene. 
Sequence Determination.  The sequences of the two posi- 
tive  clones were determined  and a  search of the  GenBank 
database  indicated  that the  sequences  of both clones were 
nearly identical to that of the [~-catenin gene  (Fig.  1).  The 
DNA  sequence  obtained  for  one  of the  cDNA  clones, 
12g2, corresponded to that found between residues  15 and 
890 of the published human [3-catenin sequence, but con- 
tained  a  deletion  of 49  nucleotides  within  the  5'  untrans- 
lated  region.  When  P-,NA from the  1290  melanoma  was 
reverse  transcribed  using oligo-dT and a PCR  carried  out 
using primers which flank this region the deletion was not 
observed, however, indicating that the deletion may repre- 
sent  a  cloning artifact  (data  not shown).  The  sequence  of 
the second clone,  11al, corresponded to that of the region 
between residues 55 and 582 of the published [3-catenin se- 
quence. The 5' end of clone 11A1  contained 24 base pairs 
of unidentified  sequence,  which  could either reflect  alter- 
native processing of this gene product or may again reflect 
a cloning artifact. 
A  comparison of the  coding regions  of the  two  cDNA 
clones with  the  published  sequence  of [3-catenin  demon- 
strated  that  a  single  nucleotide  subsitution  of a  T  for a  C 
residue  was found in both of the  cDNA clones at residue 
310, resulting in a change ofserine at position 37 to phenyl- 
alanine.  To determine  if this represented  a mutation  or an 
allelic polymorphism, R.NA from autologous normal tissues 
as well  as from the  888  and  1290  melanomas was reverse 
transcribed  using  oligo-dT,  and  a  PCR  carried  out using 
two primers which flanked residue  310. The resulting 668 
base  pair  product  was  then  digested  with  XmnI,  which 
should give rise to two products of 246 and 422 base pairs, 
in the case of the previously published sequence.  The sub- 
sitution found at residue 310 in the cDNA clones that were 
isolated,  however,  eliminated  the  XmnI restriction  endo- 
nuclease site, and as a result the size of this product should 
not be altered following digestion with this enzyme. Diges- 
tion  of the PCP, products  obtained  using RNA  from au- 
tologous fibroblasts,  TIL or EBV cells  with XmnI resulted 
in two bands  of the  expected size based on the published 
[3-catenin  sequence.  Digestion  of the  PCR  products  de- 
rived from the  1290 melanoma RNA  with XmnI resulted 
in a product of approximately 700 base pairs,  correspond- 
ing  to  the  undigested  product,  as  well  as  two  bands  of 
about 250 and 400 base pairs (Fig. 2).  The observation that 
the  undigested product was found in  the  samples  derived 
from the melanoma but not the normal tissues from patient 
888  indicated  that this  represented  a mutation  and not an 
allelic  polymorphism.  In addition,  the  1290 melanoma ap- 
peared to express the allelic  [~-catenin gene product which 
did  not  contain  this  mutation.  The  same  pattern  was ob- 
served  for the  888  melanoma that had been  isolated from 
the  same  patient  three  years  earlier  than  the  1290  mela- 
noma. When DNA sequencing reactions were carried out 
on  the  PCR  products  obtained  from  the  1290  and  888 
melanoma, both a T  and a C  residue were observed at this 
position,  confirming the  results  of the  restriction  enzyme 
digestion (data not shown). In addition,  12 allogeneic mel- 
anomas that were examined did not exhibit this mutation, 
indicating that this  represented  a relatively rare mutational 
event (Fig. 2). 
Recognition of  Mutated ~-Catenin Sequence.  An attempt was 
then made to identify the T  cell epitope in [~-catenin rec- 
ognized by TIL  1290.  The  HLA-A24 binding  motif was 
previously shown to consist of either a phenylalanine,  leu- 
cine,  isoleucine  or tryptophan  residue  at the  last  position, 
and a tyrosine, phenylalanine,  or methionine residue at po- 
sition  two  (21).  A  peptide  containing  the  amino  acid  37 
phenylalanine at position 9 would also contain a tyrosine at 
position two, which would conform to this motif. There- 
fore,  the peptide  corresponding to residues  29 to 37  of the 
mutant sequence, SYLDSGIHF (~-cat29_37  rout), as well as the 
peptide  corresponding  to  the  normal  allele,  SYLDSGIHS, 
([~-cat29_37)  were  synthesized.  When  these  peptides  were 
tested  for  their  ability  to  sensitize  targets  for  lysis,  the 
[~-cat29-37  rout peptide was found to sensitize target cells  at a 
concentration  of 1  pg/ml  or  higher,  whereas  concentra- 
tions of i  I~g/ml or greater were required for sensitization 
of target  cells  with  the  normal  [3-cat29_37  peptide  (Fig.  3). 
Thus, TIL 1290 demonstrated 106-fold better recognition of 
the mutant peptide than the normal peptide. 
The effect of the mutation at position 37 on the affinity 
of this peptide  for the HLA-A24 class  I  allele was then as- 
Figure 2.  Analysis  of the expression of [3-catenin gene products. 5 p.g 
of total P,  NA was reverse transcribed, and a PCP, was then carried out 
using 1/10 of the product using primers 60F and 727P, as described in the 
Materials and Methods. A restriction enzyme digest of the resulting 668 
base pair product was then carried out with the enzyme XnmI and the 
products separated on a 1% agarose gel and stained with ethidium bro- 
mide. Digestion of the normal product resulted in two bands of 246 and 
422 base pairs, whereas the mutant product, which lacked the Xmnl re- 
striction site, remained at 668 base pairs. 
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Figure 3.  Titration of [3-catenin peptides for recognition by TIL. 888 
EBV B cells were incubated with the indicated concentrations of peptides 
and lysis by TILl290 was measured in a 4-h 51Cr release assay at an E/T 
ratio of 40:1. 
sessed in a competitive binding assay. This assay was set up 
using  888  EBV  B  cells  that  expressed high  levels  of the 
HLA-A24 class  I  allele  and  an  12SI-labeled peptide  previ- 
ously shown to bind HLA-A24 with high affinity (20). The 
result of this assay indicated that the  concentration  of the 
[3-cat29_37mu  t  peptide  required  for  50%  inhibition  of the 
binding of the labeled peptide was similar to that required 
for inhibition using the unlabeled standard peptide  (,'~100 
ng/ml for both peptides)  (Fig.  4).  In contrast,  the  normal 
~-cat29_37 peptide did not significantly compete for binding 
at the  highest  concentration  tested,  10  Ixg/ml. This indi- 
cated that the  mutation which  occurred at position 37  in 
the  [3-catenin polypeptide was responsible for the genera- 
tion a high affinity HLA-A24 binding peptide from a na- 
tive sequence with httle affinity for this class I allele. 
A  TIL hne  termed TIL  1541,  which  was  recently  de- 
rived from a recurrence in patient 888 that occurred three 
years after the derivation of TIL 1290.  TIL 1541  was then 
tested for recognition of the mutant catenin gene product, 
as well as oftyrosinase and p15. Transfected targets express- 
ing the mutant [3-catenin gene product were recognized by 
TIL  1541,  whereas  transfectants  expressing  tyrosinase  or 
p15  failed to  stimulate  any release of GM-CSF  from this 
TIL (Table  2).  In addition,  TIL  1541  was  found  to  lyse 
HLA-A24 + 888 EBV B  cells when incubated with as httle 
as 0.1  pg/ml of the  ~-cat29_37mu  t peptide, whereas concen- 
trations of 1 I~g/ml or greater were required  for recogni- 
tion of cells pulsed with the normal ~3-cat29_37 peptide (data 
not shown), similar to results found with TIL 1290. 
In the  cytokine assay  in  Table 2,  strong stimulation  of 
TIL  1290  was  found  with  transfectants  of the  p15  gene, 
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Figure 4.  Competitive binding assay. The indicated peptides were di- 
luted and tested for their ability to inhibit the binding of the labeled stan- 
dard peptide AYIDNYNKF to 888 EBV B cells as described in the Mate- 
rials  and Methods.  The  average  total  and  non-specifically bound  cpm 
were  3,738  and 75  cpm, respectively. Non-specific binding was deter- 
mined by incubating cells with the labeled peptide in the presence of 100 
~g/ml of the cold standard peptide. 
whereas transfectants of the  [3-catenin gene product were 
only weakly recognized. This assay was carried out using a 
51-d-old culture  of TIL 1290,  whereas the previous assay 
(Table 1) was carried out using a 38-d-old culture of TIL. 
The result of this as well as additional assays have demon- 
strated loss of reactivity with 13-catenin  between seven and 
eight weeks of culture of TIL 1290, whereas reactivity with 
p15 was maintained for several additional weeks (data not 
shown).  The loss of reactivity may have resulted from the 
slower growth or more hmited hfespan of [3-catenin-reac- 
tive T  cells relative to other T  cells present in this culture. 
The fresh un-cultured  1541  tumor was also analyzed for 
expression of the normal and mutated 13-catenin  sequence, 
in order to determine whether or not immunoselection of 
an antigen loss variant had occurred in vivo following treat- 
ment of the patient three years earlier with TIL 1290.  The 
result  of this  analysis  indicated  that  the  1541  tumor  ex- 
pressed the normal as well as the mutated [3-catenin gene 
product (Fig.  5). 
Discussion 
This report demonstrates that the mutated product of the 
[3-catenin  gene was recognized by the melanoma-specific 
TIL 1290.  The mutation described in the [3-catenin gene 
appeared  to  convert  a  peptide  from  a  very  low  affinity 
binder to a very high affinity binder of the HLA-A24 class I 
gene product. Extremely high levels of  the normal [~-cat29_37 
peptide were shown to be required to sensitize target cells Table 2.  Antigen  Recognition by TIL 888,  1290, and 1541 
Stimulator  Transfected 
cell line  gene 
GM-CSF Release 
HLA-A24 TIL 888  TIL 1290  TIL 1541 
293-A24  p15  +  <8 
293-A24  13-catenin  +  <8 
293-A24  Tyrosinase  +  2,400 
293-A24  None  +  <8 
888 mel  None  +  5,000 
397  None  -  <8 
none  None  -  <8 
mal and mutant peptides from CDK4 to sensitize targets for 
lysis  than was seen  for the  13-catenin peptides.  The  muta- 
tions in the CDK4 gene as well as in 13-catenin involved a 
C-T transition at a dipyrimidine site, which may be associ- 
ated with UV-induced damge in skin cancer (22). 
The  13-catenin  gene  product  has  been  shown  to  be  an 
pg/ml  intracellular  protein  involved  in  cell-cell  adhesion.  This 
1,360  <8  protein binds to the cytoplasmic tail  of cadherins,  a family 
120  1,850  of cell  surface  proteins  involved in  cell-cell  adhesion  in  a 
11  <8  variety ofceU types  (16).  The  ~-catenin product has been 
9  <8  shown  to bind to another intracellular  protein,  ot-catenin, 
930  3,100  and this complex appears to bind to intracellular  actin mi- 
crofilaments. We do not know whether the J3-catenin mu- 
<8  <8  tation  described  in  this  report  affects  the  function  of this 
11  <8  molecule. Frequent mutations of the epithehal cell adhesion 
molecule E-cadherin have been observed in certain cancers 
such  as  gastric  carcinomas  (23),  and  some  studies  suggest 
that disruption of the function of this gene product may play 
a  role  in  cell  metastasis  (24).  Mutations  of the  J3-catenin 
gene (25) and ot-catenin gene (26) have been found in tumor 
cells and appeared to be associated with a loss of cell adhesive- 
ness. Thus, the alteration of  the normal function of {3-catenin 
could be involved in development of the malignant pheno- 
type, and it would be of interest to determine whether ad- 
ditional  mutations  in  either  the  [~-catenin  gene  or  genes 
encoding  other  member  of cell  adhesion  complexes  are 
present  in  other melanomas.  The product of the APC tu- 
mor suppressor gene has been shown to bind to 13-catenin 
(27),  and  additional  studies  have  demonstrated  binding  of 
[3-catenin  to  the  EGF  receptor  (28).  These  observations 
suggest that [~-catenin may play multiple roles in intracellu- 
lar signalling pathways, and provide other potential roles by 
which disruption of the function of this molecule could be 
involved in malignancy. 
The TIL 1541 cell line, which was derived from a recent 
recurrence in patient 888, was also found to strongly recog- 
nized the  ~-cat29_37mu t peptide, but failed to recognize tyro- 
sinase  or p15, two antigens previously shown to be recog- 
nized by TIL from this  patient.  It is  difficult to  assess  the 
significance of this  observation, since it is unclear whether 
the specificity of T  cells isolated from TIL cultures reflects 
all of the specificity of T  cells in vivo. The observation that 
the  888  tumor,  as well as the recurent  1290  and  1541  tu- 
mors,  expressed  the  mutated  [~-catenin  sequence  indicates 
that reactivity of TIL with this epitope did not result in the 
selection of antigen loss variants in vivo, however, the level 
of expression of  this epitope on the surface of tumor cells in 
vivo may be  insufficient  to  allow  efficient  recognition by 
specific T  cells.  Expression of the mutated gene could also 
be involved with maintaining the malignant phenotype,  as 
described  above,  resulting  in  selection  of tumor  cells  that 
express this protein. 
The demonstration in this report,  as well as two others, 
that melanoma-reactive T  cells  can recognize the products 
of mutated  genes  raises  the  possibility  that  many patients 
with melanoma, as well as other tumors types, may contain 
T  cells that react with  mutant  antigens.  If certain  proteins 
contain common mutations which give rise  to T  cell  epi- 
Recognition of a Mutated Gene Product by Tumor Infiltrating Lymphocytes 
The cytokine release from TIL stimulated by 293-A24 transfectants fol- 
lowing coincubation with  TIL was measured after 24  h.  The  12c2 
13-catenin cDNA construct was transfected in this assay. 
for lysis,  and thus the non-mutated gene product may not 
be expressed  at sufficient levels in normal cells  to result in 
the processing and presentation of this peptide in association 
with  HLA-A24.  Two  recent  reports  have  demonstrated 
that melanoma-reactive T  cells respond to products of mu- 
tated genes. In one, a mutant epitope derived from a previ- 
ously  unkown  gene,  termed  MUM-l,  was  shown  to  be 
recognized by HLA-B44 class I restricted,  melanoma-reac- 
tive  T  cells  (13).  A  point  mutation  was found in  this  se- 
quence that altered the amino acid sequence of the peptide 
epitope.  The known primary anchor residues were not al- 
tered in this sequence, and the normal and mutant peptides 
bound equivalendy to HLA-B44. Since the normal peptide 
was not recognized by melanoma-reactive T  cells,  this mu- 
tation appeared to have altered a T  cell contact residue.  In 
the second report,  T  cells were shown to recognize a mu- 
tated cyclin-dependent kinase 4 (CDK4) gene product (14). 
The  mutation  present  in  this  gene  product  gave  rise  to  a 
peptide  with  increased  binding to  HLA-A2.1,  although  a 
less  dramatic  difference was seen in the  ability of the nor- 
Figure 5.  Expression  of[3-cate- 
nin sequences in 1290 and 1541 
melanoma. Analysis  of  and diges- 
tion  of RT-PCR.  products was 
carried out  as  described in  the 
legend to Fig. 2.  Lane 1,  1290 
reel  IkT-PCR  product  uncut; 
lane 2, 1290 mel RT-PClk prod- 
uct digested with XnmI; lane 3, 
1541 mel RT-PCK product un- 
cut; lane 4,  1541 mel tLT-PCR 
product digested with XmnI. 
1190 topes,  they  could  potentially lead to  the  development of 
useful therapeutic reagents.  These  epitopes should also be 
truly tumor specific, which may help to avoid the develop- 
ment  of  potentially  destructive  auto-immune  responses 
which could occur when patients are immunized with an- 
tigens expressed on normal tissues such as melanocytes and 
retina.  In addition, the high frequency of mutations found 
in tumors of many different histologies raises the possibility 
that T  cells may be present in many of these patients which 
recognize mutated products, and that some relatively com- 
mon mutations could serve as the targets of additional anti- 
tumor vaccines. 
We would like to thank Dr. Hiroshi Sakamoto and Dr. Maria Parkhurst for their help in synthesis, analysis, 
and purification ofpeptides. 
Address correspondence to Dr. P.F. Robbins, Surgery Branch, National Cancer Institute, National Institutes 
of Health, Bldg. 10 Rm. 2B42, Bethesda,  MD 20892. 
Received  for publication  21 September 1995 and in revised  form 26 October 1995. 
References 
1.  Szikora, J.p., A. Van Pel, and T. Boon.  1993.  Turn-  muta- 
tion P35B  generates the MHC-binding site of a new  anti- 
genic peptide, lmmunogenetics. 37:135-138. 
2.  Lurquin, C., A. Van Pel, B. Mariame, E. De Plaen, J.-p. Szi- 
kora, C. Janssens,  M.J. Reddehase, J. Lejeune, and T. Boon. 
1989.  Structure of the gene of turn-  transplantation antigen 
P91A: The mutated exon encodes a peptide recognized with 
L  d by cytolytic T cells. Cell. 58:293-303. 
3.  Van Den Eynde, B., B. Lethe, A. Van Pel, E. De Plaen, and 
T. Boon. 1991.  The gene coding for a major tumor rejection 
antigen of tumor P815 is identical to the normal gene ofsyn- 
geneic DBA/2 mice.J. Exp. Med.  173:1373-1384. 
4.  Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, 
E.  DePlaen, B.  Van  Den  Eynde,  A.  Knuth,  and T.  Boon. 
1991.  A gene encoding an antigen recognized by cytolytic T 
lymphocytes on a human melanoma. Science (Wash. DC). 254: 
1643-1647. 
5.  Gaugler,  B.,  B.  Van  Den  Eynde,  P.  Van  der Bruggen,  P. 
Romero, J.J.  Gaforio, E. DePlaen, B. Lethe, F. Brasseur, and 
T. Boon.  1994.  Human gene MAGE-3 codes for an antigen 
recognized on a  melanoma by autologous cytolytic T  lym- 
phocytes.J. Exp.  Med.  179:921-930. 
6.  Boel,  P.,  C.  Wildmann,  M.L.  Sensi,  R.  Brasseir.  J.-C. 
Renauld,  P.  Coulie,  T.  Boon,  and  P.  Van  der  Bruggen. 
1995. BAGE: a new gene encoding an antigen recognized on 
human melanomas by cytolytic T  lymphocytes. Immunity.  2: 
167-175. 
7.  Van Den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, 
S. Lucas,  and T. Boon.  1995.  A new family of genes coding 
for an antigen recognized by autologous cytolytic T lympho- 
cytes on a human melanoma.J. Exp. Med.  182:689-698. 
8.  Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. DePlaen, 
B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene 
codes for an antigen recognized by autologous cytolytic T lym- 
phocytes on HLA-A2 melanomas.J. Exp. Med. 178:489-495. 
9.  Robbins, P.F., M. E1-Gamil, Y. Kawakami, and S.A. Rosen- 
berg.  1994.  Recognition of tyrosinase by tumor infiltrating 
lymphocytes from a patient responding to immunotherapy. 
Cancer Res. 54:3124--3126. 
10. Kawakami, Y., S. Eliyahu, C.H.  Delgaldo, P.F. Robbins, L. 
Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. 
Cloning of the gene coding for a shared human  melanoma 
1191  Robbins et al. 
antigen recognized by autologous T  cells infiltrating into tu- 
mor. Proc. Natl. Acad. Sci. USA. 91:3515-3519. 
11. Kawakami, Y., S. Eliyahu, C.H.  Delgado, P.F. Robbins, K. 
Sakaguchi,  E.  Appella, J.R.  Yannelli,  T.  Miki,  and  S.A. 
Rosenberg.  1994.  Identification of a human melanoma anti- 
gen recognized by tumor infiltrating lymphocytes associated 
with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91: 
6458-6462. 
12. Wang,  R.F.,  P.F. Robbins, Y.  Kawakami, X.Q.  Kang, and 
S.A. Rosenberg.  1995.  Identification of a  gene  encoding a 
melanoma tumor antigen recognized by HLA-A31-restricted 
tumor-infiltrating lymphocytes.  J. Exp. Med.  181:799-804. 
13. Coulie, P.G., F. Lehmann, B. Lethe, J. Herman, C. Lurquin, 
M.  Andrawiss,  and  T.  Boon.  1995.  A  mutated  intron  se- 
quence codes for an antigenic peptide recognized by cytolytic 
T  lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. 
USA. 92:7976-7980. 
14. Wolfel, T., M. Hauer, J. Schneider, M.  Serrano, C. Wolfel, 
E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K.-H. Meyer 
zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insen- 
sitive CDK4 mutant targeted by cytolytic T lymphocytes in a 
human melanoma. Science (Wash. DC). 269:1281-1284. 
15. Robbins, P.F., M.  E1-Gamil, Y.F. Li, S.L.  Topalian, L.  Ri- 
voltini, K.  Sakaguchi,  E.  AppeUa,  Y.  Kawakami,  and  S.A. 
Rosenberg.  1995.  Cloning of a new gene encoding an anti- 
gen  recognized by  melanoma-specific HLA-A24  restricted 
tumor-infiltrating lymphocytes.  J. Immunol. 154:5944-5950. 
16. Grunwald, G.B.  1993.  The structural and functional analysis 
ofcadherin calcium-dependent cell adhesion molecules. Curt. 
Opin.  Cell Biol. 5:797-805. 
17. Rosenberg,  S.A.,  B.S.  Packard,  P.M.  Aebersold,  D.  Sol- 
omon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. 
Yang, C.A. Seipp et al.  1988.  Use of tumor infiltrating lym- 
phocytes and interleukin-2 in the immunotherapy of patients 
with  metastatic melanoma.  Preliminary report.  N.  Engl. J. 
Med. 319:1676-1680. 
18. Altschul, S.F., W.  Gish, W.  Miller, E.W.  Myers,  and  D.J. 
Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 
215:403-410. 
19. Del Guercio, M.F., J. Sidney, G. Hermason, C. Perez, H.M. 
Grey, Kubo, R.T., and A. Sette.  1995.  Binding of a peptide 
antigen to multiple HLA alleles allows definition of an A2- hke supertype.J, lmmunol.  154:685-693. 
20. Kondo, A., J. Sidney, S. Southwood, M.-F. del Guercio, E. 
Appella, H. Sakamoto, and E.  Celis.  1995.  Prominent roles 
of secondary anchor  residues in  peptide binding to  HLA- 
A'2401 human class I molecules..], lmmunot. 155:4307-4312. 
21. Kubo, R.T., A. Sette, H.M. Grey, E. Appella, K. Sakaguchi, 
N-Z. Zhu, and D. Arnott, N. Sherman, J.  Shabanowitz, H. 
Michel, W.M.  Bodnar,  T.A.  Davis, and D.F.  Hunt.  1994. 
Definition of specific peptide moti~ for four major HLA-A 
alleles.J. Immunol.  152:3913-3924. 
22. Brash, D.E., J.A. Rudolph, J.A. Simon, A. Lin, G.J. McKenna, 
H.P.  Baden,  A.J.  Halperin, and J.  Ponten.  1991.  A  role of 
sunlight in skin cancer: UV-induced p53 mutations in squa- 
mous cell carcinoma. Proc. Natl.  Acad.  Sci. USA.  88:10124- 
10128. 
23. Becker,  K.-F.,  M.J.  Atkinson,  U.  Reich,  I.  Becker,  H. 
Nekarda, J.R. Siewert, and H. Hofler. 1994. E-cadherin gene 
mutations  provide clues to  diffuse type gastric carcinomas. 
Cancer Res.  54:3845-3852. 
24. Vleminckx, K., L. Vakaet Jr.,  M.  Mareel, W.  Fiefs, and F. 
Van Roy. 1991.  Genetic manipulation of E-cadherin expres- 
sion by epithehal tumor cells reveals an invasion suppressor 
role. Cell. 66:107-119. 
25. Kawanishi, J., J. Kato, K. Sasaki, S. Fujii, N. Watanabe, and 
Y. Niitsu.  1995.  Loss of E~  cell-cell ad- 
hesion due to mutation of the 13-catenin  gene in a  human 
cancer cell line, HSC-39. Mol.  Cell Biol.  15:1175-1181. 
26. Oda, T., Y. Kanai, Y. Shimoyama, A. Nagafucki, S. Tsukita, 
and  S.  Hirohashi.  1993.  Cloning of the  human  ~x-catenin 
cDNA and its aberrant mRNA in a human cancer cell line. 
Biochem. Biophys.  Res.  Comm.  193:897-904. 
27.  Su, L.-K., B.  Vogelstein, and K.W. Kinzler.  1993.  Associa- 
tion of the APC tumor suppressor protein with catenins. Sci- 
ence (Wash. DC). 262:1734-1737. 
28. Hoschuetzky, H., H. Aberle, and R_ Kemler.  1994.  j3-cate- 
nin mediates the interaction of the cadherin-catenin complex 
with  epidermal growth  factor  receptor. J.  Cell  Biol.  127: 
1375-1380. 
1192  Recognition of a Mutated Gene Product by Tumor Infiltrating Lymphocytes 